Research across Pneumonia
Related studies from across the Pneumonia family.
5 trials tracked for viral pneumonia: 1 in phase 3 or 4 and 1 with published results. The most-cited published study has 10 citations.
Showing the 5 most-cited and recently-updated of 5 trials. Browse the full registry →
Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.
Clinical data regarding Reparixin in patients with viral pneumonia did not demonstrate a statistically significant difference in the proportion of patients alive and free of respiratory failure at Day 28 (p=0.216) or Day 60 (p=0.377) 1.
Mortality rates up to Day 28 for patients treated with Reparixin did not show a statistically significant difference (p=0.17) 1.
AI synthesis of 5 cited trials, updated Jun 29, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.
Related studies from across the Pneumonia family.